Serotype-Specific Changes in Invasive Pneumococcal Disease after Pneumococcal Conjugate Vaccine Introduction: A Pooled Analysis of Multiple Surveillance Sites

English version České info

Background:
Vaccine-serotype (VT) invasive pneumococcal disease (IPD) rates declined substantially following introduction of 7-valent pneumococcal conjugate vaccine (PCV7) into national immunization programs. Increases in non-vaccine-serotype (NVT) IPD rates occurred in some sites, presumably representing serotype replacement. We used a standardized approach to describe serotype-specific IPD changes among multiple sites after PCV7 introduction.

Methods and Findings:
Of 32 IPD surveillance datasets received, we identified 21 eligible databases with rate data ≥2 years before and ≥1 year after PCV7 introduction. Expected annual rates of IPD absent PCV7 introduction were estimated by extrapolation using either Poisson regression modeling of pre-PCV7 rates or averaging pre-PCV7 rates. To estimate whether changes in rates had occurred following PCV7 introduction, we calculated site specific rate ratios by dividing observed by expected IPD rates for each post-PCV7 year. We calculated summary rate ratios (RRs) using random effects meta-analysis. For children <5 years old, overall IPD decreased by year 1 post-PCV7 (RR 0·55, 95% CI 0·46–0·65) and remained relatively stable through year 7 (RR 0·49, 95% CI 0·35–0·68). Point estimates for VT IPD decreased annually through year 7 (RR 0·03, 95% CI 0·01–0·10), while NVT IPD increased (year 7 RR 2·81, 95% CI 2·12–3·71). Among adults, decreases in overall IPD also occurred but were smaller and more variable by site than among children. At year 7 after introduction, significant reductions were observed (18–49 year-olds [RR 0·52, 95% CI 0·29–0·91], 50–64 year-olds [RR 0·84, 95% CI 0·77–0·93], and ≥65 year-olds [RR 0·74, 95% CI 0·58–0·95]).

Conclusions:
Consistent and significant decreases in both overall and VT IPD in children occurred quickly and were sustained for 7 years after PCV7 introduction, supporting use of PCVs. Increases in NVT IPD occurred in most sites, with variable magnitude. These findings may not represent the experience in low-income countries or the effects after introduction of higher valency PCVs. High-quality, population-based surveillance of serotype-specific IPD rates is needed to monitor vaccine impact as more countries, including low-income countries, introduce PCVs and as higher valency PCVs are used.

Please see later in the article for the Editors' Summary

Vyšlo v časopise: Serotype-Specific Changes in Invasive Pneumococcal Disease after Pneumococcal Conjugate Vaccine Introduction: A Pooled Analysis of Multiple Surveillance Sites. PLoS Med 10(9): e32767. doi:10.1371/journal.pmed.1001517
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pmed.1001517

Souhrn

Zdroje

1. World Health Organization (2012) Estimated Hib and pneumococcal deaths for children under 5 years of age, 2008. Available: http://www.who.int/immunization_monitoring/burden/Pneumo_hib_estimates/en/index.html. Accessed 18 February 2013.

2. PilishviliT, LexauC, FarleyMM, HadlerJ, HarrisonLH, et al. (2010) Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 201: 32–41.

3. KellnerJD, VanderkooiOG, MacDonaldJ, ChurchDL, TyrrellGJ, et al. (2009) Changing epidemiology of invasive pneumococcal disease in Canada, 1998–2007: update from the Calgary-area Streptococcus pneumoniae research (CASPER) study. Clin Infect Dis 49: 205–212.

4. SingletonRJ, HennessyTW, BulkowLR, HammittLL, ZulzT, et al. (2007) Invasive pneumococcal disease caused by nonvaccine serotypes among Alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage. JAMA 297: 1784–1792.

5. O’BrienKL, MillarEV, ZellER, BronsdonM, WeatherholtzR, et al. (2007) Effect of pneumococcal conjugate vaccine on nasopharyngeal colonization among immunized and unimmunized children in a community-randomized trial. J Infect Dis 196: 1211–1220.

6. HuangSS, PlattR, Rifas-ShimanSL, PeltonSI, GoldmannD, et al. (2005) Post-PCV7 changes in colonizing pneumococcal serotypes in 16 Massachusetts communities, 2001 and 2004. Pediatrics 116: e408–e413.

7. FlascheS, Van HoekAJ, SheasbyE, WaightP, AndrewsN, et al. (2011) Effect of pneumococcal conjugate vaccination on serotype-specific carriage and invasive disease in England: a cross-sectional study. PLoS Med 8: e1001017 doi:10.1371/journal.pmed.1001017

8. O'BrienKL, WolfsonLJ, WattJP, HenkleE, Deloria-KnollM, et al. (2009) Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet 374: 893–902.

9. AbdullahiO, KaraniA, TigoiCC, MugoD, KunguS, et al. (2012) The prevalence and risk factors for pneumococcal colonization of the nasopharynx among children in Kilifi District, Kenya. PLoS One 7: e30787 doi:10.1371/journal.pone.0030787

10. World Health Organization (2010) Changing epidemiology of pneumococcal serotypes after introduction of conjugate vaccine: July 2010 report. Wkly Epidemiol Rec 85: 434–436.

11. Conklin L, Knoll MD, Loo JD, Fleming-Dutra K, Park D, et al.. (2011) Landscape analysis of pneumococcal conjugate vaccine dosing schedules: A systematic review (Report to the Strategic Advisory Group of Experts on Immunization (SAGE), World Health Organization). Available: http://www.who.int/immunization/sage/3_Conklin_L_PCV_Dosing_Landscape_Report_Oct_17_2011_FINAL_nov11.pdf. Accessed 18 February 2013.

12. ParkIH, MooreMR, TreanorJJ, PeltonSI, PilishviliT, et al. (2008) Differential effects of pneumococcal vaccines against serotypes 6A and 6C. J Infect Dis 198: 1818–1822.

13. HausdorffWP, SiberG, ParadisoPR (2001) Geographical differences in invasive pneumococcal disease rates and serotype frequency in young children. Lancet 357: 950–952.

14. WeinbergerDM, MalleyR, LipsitchM (2011) Serotype replacement in disease after pneumococcal vaccination. Lancet 378: 1962–1973.

15. HanquetG, LernoutT, VergisonA, VerhaegenJ, KisslingE, et al. (2011) Impact of conjugate 7-valent vaccination in Belgium: addressing methodological challenges. Vaccine 29: 2856–2864.

16. MillerE, AndrewsNJ, WaightPA, SlackMP, GeorgeRC (2011) Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study. Lancet Infect Dis 11: 760–768.

17. CoxC (1990) Fieller’s Theorem, the Likelihood and the Delta Method. Biometrics 46: 709–718.

18. Beaton GH, United Nations. Subcommittee on Nutrition (1992) Effectiveness of vitamin A supplementation in the control of young child morbidity and mortality in developing countries. Nutrition policy discussion paper number 13. Geneva: ACC/SCN. 120p.

19. SweetingMJ, SuttonAJ, LambertPC (2004) What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. Stat Med 23: 1351–1375.

20. Borenstein M, Hedges L., Rothstein H. (2007) Introduction to meta-analysis. pp.2–303. Available: http://www.meta-analysis.com/downloads/Meta%20Analysis%20Fixed%20vs%20Random%20effects.pdf. Accessed 18 February 2013.

21. KrauseVL, ReidSJ, MerianosA (2000) Invasive pneumococcal disease in the Northern Territory of Australia, 1994–1998. Med J Aust 173 Suppl: S27–31.

22. BarryC, KrauseVL, CookHM, MenziesRI (2012) Invasive pneumococcal disease in Australia 2007 and 2008. Commun Dis Intell Q Rep 36: E151–165.

23. MotlovaJ, BenesC, KrizP (2009) Incidence of invasive pneumococcal disease in the Czech Republic and serotype coverage by vaccines, 1997–2006. Epidemiol Infect 137: 562–569.

24. HarboeZB, Valentiner-BranthP, IngelsH, RasmussenJN, AndersenPH, et al. (2013) Pediatric invasive pneumococcal disease caused by vaccine serotypes following the introduction of conjugate vaccination in Denmark. PLoS ONE 8: e51460 doi:10.1371/journal.pone.0051460

25. GrallN, HurmicO, Al NakibM, LongoM, PoyartC, et al. (2011) Epidemiology of Streptococcus pneumoniae in France before introduction of the PCV-13 vaccine. Eur J Clin Microbiol Infect Dis 30: 1511–1519.

26. ZissisNP, SyriopoulouV, KafetzisD, DaikosGL, TsilimingakiA, et al. (2004) Serotype distribution and antimicrobial susceptibility of Streptococcus pneumoniae causing invasive infections and acute otitis media in children. Eur J Pediatr 163: 364–368.

27. VickersI, FitzgeraldM, MurchanS, CotterS, O'FlanaganO’FlanaganD, et al. (2011) Serotype distribution of Streptococcus pneumoniae causing invasive disease in the Republic of Ireland. Epidemiol Infect 139: 783–790.

28. Ben-ShimolS, GreenbergD, Givon-LaviN, EliasN, GlikmanD, et al. (2012) Rapid reduction in invasive pneumococcal disease after introduction of PCV7 into the National Immunization Plan in Israel. Vaccine 30: 6600–6607.

29. van DeursenAM, van MensSP, SandersEA, VlaminckxBJ, de MelkerHE, et al. (2012) Invasive pneumococcal disease and 7-valent pneumococcal conjugate vaccine, the Netherlands. Emerg Infect Dis 18: 1729–1737.

30. HeffernanHM, MartinDR, WoodhouseRE, MorganJ, BlackmoreTK (2008) Invasive pneumococcal disease in New Zealand 1998–2005: capsular serotypes and antimicrobial resistance. Epidemiol Infect 136: 352–359.

31. VestrheimDF, LovollO, AabergeIS, CaugantDA, HoibyEA, et al. (2008) Effectiveness of a 2+1 dose schedule pneumococcal conjugate vaccination programme on invasive pneumococcal disease among children in Norway. Vaccine 26: 3277–3281.

32. Lamb KE, Flasche S, Diggle M, Inverarity D, Greenhalgh D, et al.. (2013) Trends in serotypes and sequence types among cases of invasive pneumococcal disease in Scotland, 1999–2010. Vaccine. In press.

33. PilishviliT, ZellER, FarleyMM, SchaffnerW, LynfieldR, et al. (2010) Risk factors for invasive pneumococcal disease in children in the era of conjugate vaccine use. Pediatrics 126: e9–e17.

34. WeatherholtzR, MillarEV, MoultonLH, ReidR, RudolphK, et al. (2010) Invasive pneumococcal disease a decade after pneumococcal conjugate vaccine use in an American Indian population at high risk for disease. Clin Infect Dis 50: 1238–1246.

35. BlackS, FranceEK, IsaacmanD, BrackenL, LewisE, et al. (2007) Surveillance for invasive pneumococcal disease during 2000–2005 in a population of children who received 7-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J 26: 771–777.

36. ByingtonCL, SamoreMH, StoddardGJ, BarlowS, DalyJ, et al. (2005) Temporal trends of invasive disease due to Streptococcus pneumoniae among children in the intermountain west: emergence of nonvaccine serogroups. Clin Infect Dis 41: 21–29.

37. GAVI Alliance (2011) GAVI Alliance Country Eligibility Policy. Available: www.gavialliance.org/about/governance/programme-policies/country-eligibility/. Accessed 31 May 2013.

38. BlackS (2010) The volatile nature of pneumococcal serotype epidemiology: potential for misinterpretation. Pediatr Infect Dis J 29: 301–303.

39. World Health Organization (2012) Pneumococcal vaccine WHO position paper - 2012. Wkly Epidemiol Rec 14: 129–144.

40. MillerE, AndrewsNJ, WaightPA, SlackMP, GeorgeRC (2011) Effectiveness of the new serotypes in the 13-valent pneumococcal conjugate vaccine. Vaccine 29: 9127–9131.

41. PalmuAA, JokinenJ, BorysD, NieminenH, RuokokoskiE, et al. (2012) Effectiveness of the ten-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against invasive pneumococcal disease: a cluster randomised trial. Lancet 381: 214–222.

42. SingletonR, WengerJ, KlejkaJA, BulkowLR, ThompsonA, et al. (2013) The 13-valent pneumococcal conjugate vaccine for invasive pneumococcal disease in Alaska Native children: results of a clinical trial. Pediatr Infect Dis J 32: 257–263.

43. BrueggemannAB, PetoTE, CrookDW, ButlerJC, KristinssonKG, et al. (2004) Temporal and geographic stability of the serogroup-specific invasive disease potential of Streptococcus pneumoniae in children. J Infect Dis 190: 1203–1211.

44. BogaertD, ThompsonCM, TrzcinskiK, MalleyR, LipsitchM (2010) The role of complement in innate and adaptive immunity to pneumococcal colonization and sepsis in a murine model. Vaccine 28: 681–685.

45. SleemanKL, GriffithsD, ShackleyF, DiggleL, GuptaS, et al. (2006) Capsular serotype-specific attack rates and duration of carriage of Streptococcus pneumoniae in a population of children. J Infect Dis 194: 682–688.

46. WeinbergerDM, HarboeZB, FlascheS, ScottJA, LipsitchM (2011) Prediction of serotypes causing invasive pneumococcal disease in unvaccinated and vaccinated populations. Epidemiology 22: 199–207.

47. WhitneyCG, FarleyMM, HadlerJ, HarrisonLH, BennettNM, et al. (2003) Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 348: 1737–1746.

48. HsuHE, ShuttKA, MooreMR, BeallBW, BennettNM, et al. (2009) Effect of pneumococcal conjugate vaccine on pneumococcal meningitis. N Engl J Med 360: 244–256.

49. CohenAL, HarrisonLH, FarleyMM, ReingoldAL, HadlerJ, et al. (2010) Prevention of invasive pneumococcal disease among HIV-infected adults in the era of childhood pneumococcal immunization. AIDS 24: 2253–2262.

50. FeikinDR, KlugmanKP (2002) Historical changes in pneumococcal serogroup distribution: implications for the era of pneumococcal conjugate vaccines. Clin Infect Dis 35: 547–555.

51. FenollA, Martin BourgonC, MunozR, ViciosoD, CasalJ (1991) Serotype distribution and antimicrobial resistance of Streptococcus pneumoniae isolates causing systemic infections in Spain, 1979–1989. Rev Infect Dis 13: 56–60.

52. HarboeZB, BenfieldTL, Valentiner-BranthP, HjulerT, LambertsenL, et al. (2010) Temporal trends in invasive pneumococcal disease and pneumococcal serotypes over 7 decades. Clin Infect Dis 50: 329–337.

53. LagosR, MunozA, San MartinO, MaldonadoA, HormazabalJC, et al. (2008) Age- and serotype-specific pediatric invasive pneumococcal disease: insights from systematic surveillance in Santiago, Chile, 1994–2007. J Infect Dis 198: 1809–1817.

54. HausdorffWP, FeikinDR, KlugmanKP (2005) Epidemiological differences among pneumococcal serotypes. Lancet Infect Dis 5: 83–93.

55. DaganR, Givon-LaviN, LeibovitzE, GreenbergD, PoratN (2009) Introduction and proliferation of multidrug-resistant Streptococcus pneumoniae serotype 19A clones that cause acute otitis media in an unvaccinated population. J Infect Dis 199: 776–785.

56. Hausdorff WP, Van Dyke MK, Van Effelterre T (2012) Serotype replacement after pneumococcal vaccination. Lancet 379: : 1387–1388; author reply 1388–1389.

57. BlackRE, CousensS, JohnsonHL, LawnJE, RudanI, et al. (2010) Global, regional, and national causes of child mortality in 2008: a systematic analysis. Lancet 375: 1969–1987.

58. World Health Organization (2012) Review of serotype replacement in the setting of 7-valent pneumococcal conjugate vaccine (PCV-7) use and implications for the PCV10/PCV13 era. Wkly Epidemiol Rec 87: 12–13.

59. RobinsonKA, BaughmanW, RothrockG, BarrettNL, PassM, et al. (2001) Epidemiology of invasive Streptococcus pneumoniae infections in the United States, 1995-1998: Opportunities for prevention in the conjugate vaccine era. JAMA 285: 1729–1735.

60. van DeursenAM, van MensSP, SandersEA, VlaminckxBJ, de MelkerHE, et al. (2012) Invasive pneumococcal disease and 7-valent pneumococcal conjugate vaccine, the Netherlands. Emerg Infect Dis 18: 1729–1737.